Show simple item record

dc.contributor.authorHierro Bujalance, Carmen
dc.contributor.authorGarcía Alloza, Mónica 
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2024-05-02T12:14:12Z
dc.date.available2024-05-02T12:14:12Z
dc.date.issued2024
dc.identifier.issn1876-7958
dc.identifier.issn1673-5374
dc.identifier.urihttp://hdl.handle.net/10498/32070
dc.description.abstractAlzheimer’s disease (AD) and type 2 diabetes (T2D): More than 55 million people suffer from dementia, and it is expected that over 150 million people will suffer from this disease by 2050. AD is the most common type of dementia and while aging remains the main risk factor to suffer it, previous studies have also shown that metabolic disorders, and T2D specifically, are also major contributors (Wang et al., 2012). The prevalence of diabetes has reached 537 million people worldwide and these figures are expected to keep rising (Ahmad et al., 2022). All things considered, both diseases are a great challenge for health.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherWolters Kluwer Medknow Publicationses_ES
dc.rightsAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.sourceNeural Regeneration Research - 2024, Vol. 19 n. 6, pp. 1189 - 1190es_ES
dc.titleEmpagliflozin reduces brain pathology in Alzheimer’s disease and type 2 diabeteses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.4103/1673-5374.385865
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-115499RB-I00/ES/COMPLICACIONES TEMPRANAS EN LA ENFERMEDAD DE ALZHEIMER Y EN DIABETES MELLITUS TIPO 2: IMPLICACIONES FARMACOLOGICAS/ es_ES
dc.type.hasVersionVoRes_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This work is under a Creative Commons License Atribución-NoComercial-CompartirIgual 4.0 Internacional